We operate Jiarun Hospital and its two branch hospitals, collectively being a private hospital with 950 beds located in Harbin, the capital of Heilongjiang Province in northeastern China. Jiarun Hospital offers patients care and pharmaceuticals in the areas of both Western and Chinese medical practices. Jiarun specializes in Pediatrics, Dermatology, Ears, Nose and Throat (ENT), Traditional Chinese Medicine (TCM), Ophthalmology, Internal Medicine, Dentistry, General Surgery, Rehabilitation Science, Gynecology, General Medical Services, etc. Our ambulances operate 24 hours a day.
Company profile
Ticker
JRSS
Exchange
Website
CEO
Li Hua Sun
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
JRSIS Health Care Limited, a limited company • Runteng Medical Group Company Limited, a limited company • Laidian Technology (Zhongshan) Co., Ltd., a limited company ...
JRSS stock data
Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
11 Apr 24
NT 10-K
Notice of late annual filing
29 Mar 24
8-K
Departure of Directors or Certain Officers
11 Dec 23
8-K
Entry into a Material Definitive Agreement
1 Dec 23
10-Q
2023 Q3
Quarterly report
15 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
8-K
Entry into a Material Definitive Agreement
18 Oct 23
UPLOAD
Letter from SEC
29 Sep 23
10-K/A
2022 FY
Annual report (amended)
31 Aug 23
CORRESP
Correspondence with SEC
31 Aug 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.39 k | 33.39 k | 33.39 k | 33.39 k | 33.39 k | 33.39 k |
Cash burn (monthly) | (no burn) | (no burn) | 39.71 k | 32.41 k | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 264.46 k | 215.81 k | n/a | n/a |
Cash remaining | n/a | n/a | -231.08 k | -182.42 k | n/a | n/a |
Runway (months of cash) | n/a | n/a | -5.8 | -5.6 | n/a | n/a |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|